Filing Flows › Regenxbio (RGNX) › Q3 2026 › vs Q3 2025
Regenxbio (RGNX) Q3 2026 vs Q3 2025 (year over year)
Regenxbio's revenue fell $20.6M (-69%) from $29.7M in Q3 2025 to $9.2M in Q3 2026. The biggest changes: Service −$2.2M (-36%).
Regenxbio, Q3 2026: revenue $9.2M (-69% year over year), operating margin -387.8%, net loss $40.7M, operating cash flow $38.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 419.3% | -189.9% | +609.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Nippon Shinyaku Services | $3.3M | $5.9M | −$2.6M | -44% |
| Zolgensma Royalties | $2.4M | $23.6M | −$21.2M | -90% |
| Other Service Revenue | $609K | $196K | $413K | +211% |
| Service | $3.9M | $6.1M | −$2.2M | -36% |
| Revenue | $9.2M | $29.7M | −$20.6M | -69% |
| Net loss | $40.7M | $61.9M | −$21.2M | -34% |
| Costs & expenses | $49.9M | $91.7M | −$41.8M | -46% |
| Operating costs | $44.7M | $82.1M | −$37.4M | -46% |
| Interest & other, net | $5.2M | $9.5M | −$4.3M | -45% |
| Operating cash sources | $79.3M | $6.0M | $73.4M | 13× |
| Depreciation & amortization | $3.5M | $3.9M | −$371K | -10% |
| Share-based compensation | $8.1M | $9.0M | −$878K | -10% |
| Working capital & other | $67.7M | −$6.9M | $74.6M | — |
| Net loss absorbed | $40.7M | $61.9M | −$21.2M | -34% |
| Operating cash flow | $38.6M | −$56.0M | $94.6M | — |
| Free cash flow (OCF − capex) | $38.4M | −$56.5M | $94.9M | — |
| Capital expenditures | $194K | $491K | −$297K | -60% |
Questions
How much did Regenxbio's revenue grow year over year in Q3 2026?
Regenxbio's revenue fell $20.6M (-69%) from $29.7M in Q3 2025 to $9.2M in Q3 2026.
What drove Regenxbio's revenue change in Q3 2026?
Service −$2.2M (-36%).